Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice

Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid change, glucose homeost...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Geng-Ruei, Hou, Po-Hsun, Yang, Wei-Cheng, Wang, Chao-Min, Fan, Pei-Shan, Liao, Huei-Jyuan, Chen, To-Pang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001117/
https://www.ncbi.nlm.nih.gov/pubmed/33809508
http://dx.doi.org/10.3390/ph14030267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001117/
https://www.ncbi.nlm.nih.gov/pubmed/33809508
http://dx.doi.org/10.3390/ph14030267

Ejemplares similares